Tag - IMM

Immutep (ASX: IMM; NASDAQ: IMMP) has announced positive Phase 1 results for IMP761, a first-in-class LAG-3 agonist antibody designed to potentially supress pathogenic T cell responses in autoimmune diseases. According...